About US
Contact us
-
Watch out, Dupixent. Pfizer's new JAK inhibitor could come after your eczema marketPfizer’s FDA-approved JAK inhibitor Xeljanz is currently struggling with cardiovascular safety concerns. But another candidate in the family for which Pfizer has blockbuster hopes just slew a phase 32019/5/16
-
Pfizer, Merck KGaA's latest Bavencio nod sets up 3-way kidney cancer battlePfizer and its Germany-based partner Merck KGaA finally have some good news to celebrate in their long-fought battle to broaden the market for their PD-1/PD-L1 inhibitor Bavencio: an FDA approval of2019/5/15
-
B. Braun commits $1B to expand in face of IV fluid shortagesB. Braun Medical, which has been a key figure in the nation’s shortage of IV fluids, says it is committed to helping fix the problem. It will invest $1 billion in its U.S. manufacturing and supply ch2019/5/15
-
Hey, big spender: Pharma's $6.6B TV ad outlay outranks most other industries, report saysPharma is the fourth-largest spender on TV ads in the U.S., with $6.6 billion spent over the past year. That’s according to MediaRadar’s annual study of TV ad spending, which includes OTC drug ads in2019/5/14
-
Bayer's already in the hot seat with investors. A new $2B Roundup slapdown won't helpWith angry investors at the gates and thousands of lawsuits tied up in court, Bayer’s executives have scrambled to keep their head above water. Looks like relief isn’t coming any time soon, at least2019/5/14
-
BMS’ Opdivo fails in Phase III glioblastoma trialBristol-Myers Squibb (BMS) has announced that its immunotherapy drug Opdivo (nivolumab) has failed to meet its primary endpoint of overall survival (OS) in Phase III CheckMate-498 trial. In this rand2019/5/13
-
Roche’s Ocrevus to be available on NHS EnglandNational Health Service (NHS) England has entered a deal with Roche to make the Swiss drugmaker’s Ocrevus (ocrelizumab) medicine available at a lower price for routine use. Ocrevus is indicated to tr2019/5/13
-
Pfizer to purchase biotech firm Therachon for up to $810mPfizer has agreed to acquire Swiss biotechnology firm Therachon for a total consideration of $810mto support its rare disease portfolio. The deal involves an upfront payment of$340m and a further $472019/5/10
-
Takeda to divest dry eye drug to Novartis in $5.3bn dealTakeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn. Xiidra is an anti-inflammatory medicine indicated to treat the symptoms2019/5/10
-
Sanofi gets EC approval for Dupixent to treat severe asthmaSanofi’s Dupixent has been approved by the European Commission (EC) as an add-on maintenance treatment for severe asthma in adults and adolescents. The indication includes patients with Type 2 inflam2019/5/9